Our Mission

The blood–brain barrier is a highly specialized vascular interface that protects the brain while regulating communication between the circulation and the central nervous system.

When the BBB becomes compromised:

Immune cells infiltrate the brain

Neuroinflammation increases

Neuronal damage accelerates

BBB dysfunction is now recognized as a central driver of pathology across multiple neurological diseases.

Despite this, current therapies primarily target downstream consequences rather than the barrier itself.

Phragma Therapeutics is developing therapies designed to directly restore BBB function, addressing this critical unmet need.

Our scientific strategy focuses on brain endothelial biology, the cellular foundation of the blood–brain barrier.

Brain endothelial cells regulate:

barrier permeability

immune cell entry

vascular stability

Dysfunction of these cells is one of the earliest triggers of neurological disease progression.

By selectively targeting endothelial pathways, we aims to:

restore barrier integrity

reduce pathological leakage

limit neuroinflammation

This represents a novel therapeutic axis in neurology.